Metis Global Partners LLC Sells 961 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Metis Global Partners LLC cut its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 5.8% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 15,470 shares of the medical equipment provider’s stock after selling 961 shares during the period. Metis Global Partners LLC’s holdings in Intuitive Surgical were worth $5,219,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. WCM Investment Management LLC acquired a new stake in shares of Intuitive Surgical in the fourth quarter valued at approximately $575,536,000. International Assets Investment Management LLC boosted its stake in Intuitive Surgical by 32,360.5% during the 4th quarter. International Assets Investment Management LLC now owns 686,865 shares of the medical equipment provider’s stock worth $231,721,000 after acquiring an additional 684,749 shares during the last quarter. Alphinity Investment Management Pty Ltd grew its holdings in Intuitive Surgical by 113.2% during the fourth quarter. Alphinity Investment Management Pty Ltd now owns 1,276,158 shares of the medical equipment provider’s stock valued at $430,525,000 after purchasing an additional 677,455 shares during the period. J.P. Morgan Private Wealth Advisors LLC bought a new position in shares of Intuitive Surgical during the third quarter worth $178,667,000. Finally, Quadrature Capital Ltd grew its holdings in shares of Intuitive Surgical by 466.2% in the 3rd quarter. Quadrature Capital Ltd now owns 340,644 shares of the medical equipment provider’s stock valued at $99,601,000 after buying an additional 280,480 shares during the period. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on ISRG. Wells Fargo & Company upped their price objective on Intuitive Surgical from $363.00 to $416.00 and gave the stock an “overweight” rating in a research report on Friday, January 19th. StockNews.com lowered shares of Intuitive Surgical from a “buy” rating to a “hold” rating in a research report on Thursday, February 29th. Piper Sandler raised their price objective on Intuitive Surgical from $425.00 to $435.00 and gave the company an “overweight” rating in a report on Friday, April 19th. Royal Bank of Canada boosted their target price on shares of Intuitive Surgical from $400.00 to $432.00 and gave the stock an “outperform” rating in a report on Wednesday, January 24th. Finally, Jefferies Financial Group raised their price objective on Intuitive Surgical from $365.00 to $375.00 and gave the company a “hold” rating in a research report on Friday, April 19th. Five equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, Intuitive Surgical currently has a consensus rating of “Moderate Buy” and an average price target of $396.17.

Intuitive Surgical Stock Up 1.0 %

Shares of ISRG stock traded up $3.71 during mid-day trading on Friday, reaching $381.36. 1,028,858 shares of the stock traded hands, compared to its average volume of 1,492,254. The stock’s fifty day simple moving average is $385.40 and its two-hundred day simple moving average is $350.34. Intuitive Surgical, Inc. has a 1-year low of $254.85 and a 1-year high of $403.76. The company has a market cap of $135.27 billion, a price-to-earnings ratio of 68.84, a price-to-earnings-growth ratio of 4.93 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last announced its earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 EPS for the quarter, topping the consensus estimate of $1.40 by $0.10. The firm had revenue of $1.89 billion for the quarter, compared to the consensus estimate of $1.87 billion. Intuitive Surgical had a return on equity of 12.91% and a net margin of 27.16%. The business’s quarterly revenue was up 11.5% compared to the same quarter last year. During the same period in the previous year, the business earned $1.00 EPS. On average, equities research analysts anticipate that Intuitive Surgical, Inc. will post 4.8 EPS for the current fiscal year.

Insider Buying and Selling

In related news, EVP Robert Desantis sold 1,498 shares of the firm’s stock in a transaction that occurred on Friday, April 26th. The stock was sold at an average price of $369.92, for a total transaction of $554,140.16. Following the completion of the sale, the executive vice president now owns 5,507 shares of the company’s stock, valued at $2,037,149.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, EVP Robert Desantis sold 1,498 shares of the stock in a transaction dated Friday, April 26th. The shares were sold at an average price of $369.92, for a total transaction of $554,140.16. Following the transaction, the executive vice president now owns 5,507 shares of the company’s stock, valued at approximately $2,037,149.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Marshall Mohr sold 108,790 shares of the company’s stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $385.08, for a total value of $41,892,853.20. Following the transaction, the vice president now directly owns 26,877 shares in the company, valued at $10,349,795.16. The disclosure for this sale can be found here. Insiders sold 226,928 shares of company stock valued at $87,833,828 over the last quarter. Insiders own 0.90% of the company’s stock.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.